earnings
confidence high
sentiment positive
materiality 0.75
Cerus Q1 total revenue $43.0M (+46% YoY); raises FY product revenue guidance to $160-165M
CERUS CORP
2023-Q1 EPS reported
-$0.07
- Product revenue $37.4M (+60% YoY) driven by INTERCEPT platelet kit sales in the U.S.
- Net loss improved to $12.3M ($0.07/shr) vs $17.5M ($0.10/shr) a year ago.
- Non-GAAP Adjusted EBITDA improved to -$3.7M from -$11.5M year-over-year.
- Signed multi-year INTERCEPT platelet contract with American Red Cross and 10-year Fresenius Kabi manufacturing extension.
- Cash and investments $108.6M at March 31, 2022; net cash used in operations $21.5M.